A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The stock's fall snapped a four-day winning streak.

Several companies across various sectors on the Wall Street have seen some Seeking Alpha analyst activity, including both ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients ...